Recently, it was demonstrated that exendin-4, which is a GLP-1 receptor agonist, also known as exenatide, currently prescribed to treat obesity and diabetes, reduces Na+/K+ATPase activity a marker of CSF secretion. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.